Thrombomodulin levels are not modified during thalidomide treatment

European Journal of Haematology

Volumn 77, Issue 5, 2006, Pages 453-454

  Zappasodi, Patrizia ^a   Mangiacavalli, Silvia ^a   Terulla, Virginio ^a   Airò, Francesca ^a   Klersy, Catherine ^a   Varettoni, Marzia ^a   Corso, Alessandro ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; THALIDOMIDE; THROMBOMODULIN;

ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; INTESTINE INFARCTION; LETTER; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOSIS;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIPLE MYELOMA; THALIDOMIDE; THROMBOMODULIN; THROMBOSIS;

EID: 33749246549     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00733.x     Document Type: Letter

References (6)

1. ANAGNOSTOPOULOS A, WBER D, RANKIN K, DELASALLE K, ALEXANIAN R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003;121:768-771.
2. RAJKUMAR SV, BLOOD E, VESOLE D, FONSECA R, GREIPP PR, Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern cooperative oncology group. J Clin Oncol 2006;24:334-336.
3. CAVO M, ZAMAGNI E, CELLINI C et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002;100:2272-2273.
4. CORSO A, LORENZI A, TERULLA V, AIRÒ F, VARETTONI M, MANGIACAVALLI S, ZAPPASODI P, RUSCONI C, LAZZARINO M. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with Thalidomide and Dexamethasone. Ann Hematol 2004;83:588-591.
5. SOHN RH, DEMING CB, JOHNS DC, CHAMPION HC, BIAN C, GARDNER K, RADE JJ. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood 2005;105:3910-3917.
6. ZANGARI M, SIEGEL E, BARLOGIE B, ANAISSIE E, SAGHAFIFAR F, FASSAS A, MORRIS C, FINK L, TRICOT G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002;100:1168-1171.